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Metabolic Science, Cambridge, UKIntroduction: Membranous glomerulonephritis (MGN) is rarely associated with necrotizing and crescentic
glomerulonephritis (NCGN).
Methods: We report the clinical and pathologic findings in 15 patients with MGN and NCGN associated
with anti-neutrophil cytoplasm antibodies (ANCAs), anti–glomerular basement membrane (GBM), or anti–
phospholipase A2 receptor (PLA2R) antibodies.
Results: The cohort consisted of 15 patients: 7 males and 8 females with a median age of 63 years (range: 18–
79). In 12 of 15 patients, MGN and NCGN were diagnosed at the time of the biopsy, and in 3 cases, MGN
predated the NCGN. ANCA was positive in 7 cases (6 MPOmyeloperoxidase (MPO)-ANCA and 1 PR3–ANCA),
anti-GBM antibodies were detected in 5 cases, and anti-PLA2R antibodies were found in 2 cases. One case
was negative for all antibodies. Microscopic hematuria was present in all but one patient who was anuric, and
median urinary protein-to-creatinine ratio was 819.5 mg/mmol (range: 88–5600). Pathologic evaluation
revealed MGN and NCGN with crescents involving 28% of glomeruli (median; range: 5%–100%). Follow-up
was available for all 15 patients; all were treated with steroids; 10 with cyclophosphamide, and 6 also
received rituximab. At a median follow-up of 72 months, 9 had stabilization or improvement of renal function,
6 had progressed to end-stage renal disease, and 4 died during the follow-up period.
Conclusion: MGN with crescents associated with ANCAs or anti-GBM antibodies is a rare dual glomer-
ulopathy. Patients present with heavy proteinuria, microscopic hematuria, and acute kidney injury and
should be treated for a rapidly progressive glomerulonephritis. Prognosis is variable, and 40% of patients
progress to end-stage renal disease.
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mediated glomerular disease, with antibodies against
PLA2R found in over 70% of cases of primary
MGN.1 It is characterized by the presence of subepi-
thelial immune complexes, basement membrane
damage, and proteinuria. MGN is described as primary
if there is no underlying cause, or as secondary if it
presents in association with systemic lupus erythema-
tosus (SLE), neoplasms, drugs, or infections.2 The coex-
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International Reports (2019) 4, 1577–1584of SLE it is usually associated with circulating ANCAs
or anti-GBM antibodies. Unlike MGN that typically
presents with proteinuria and edema, patients with
NCGN usually have a rapidly progressive form of
glomerulonephritis that can be life-threatening. MGN
with NCGN has also been described in the absence of
circulating ANCAs or anti-GBM antibodies3 and leads
to rapidly progressive glomerulonephritis. Although
a few case series and reports3–9 describe the pathologic
features and clinical outcomes of MGN with crescentic
glomerulonephritis in the context of anti-GBM anti-
bodies or ANCAs, little is known about the role of
anti-PLA2R Ab in this setting.10 Here, we present
the clinical, pathologic, and outcome data of 15
patients with this rare form of combined MGN
and NCGN, including patients with or without circu-
lating ANCAs, anti-GBM antibodies, or anti-PLA2R
antibodies.1577
CLINICAL RESEARCH A Nikolopoulou et al.: Membranous Glomerulonephritis With CrescentsMETHODS
A total of 5679 native biopsies were performed in our
center from January 2004 to January 2018. Fifteen
patients with renal biopsy findings of MGN with
cellular or fibrocellular crescents were identified
including 2 cases predating 2004. Patients with SLE
were excluded because of the potential presence of
crescentic and membranous changes in lupus nephritis.
All renal biopsies were processed according to stan-
dard techniques for light microscopy (LM), immuno-
peroxidase (IP), immunofluorescence (IF), and electron
microscopy (EM). For each patient, glass slides were
prepared and stained with hematoxylin and eosin, pe-
riodic acid-Schiff (PAS), trichrome, and Jones methena-
mine silver (JMS). IP was performed on 4-mm paraffin
embedded sections for IgG and C3. IF was performed on
4-mm cryostat sections using polyclonal fluorescein iso-
thiocyanate conjugated antibodies to IgG, IgM, IgA, C3,
C1q, kappa, and lambda. IF was scored by the patholo-
gist on a scale of 0 to 3þ. Electron microscopy was
performed as per clinical routine.
ANCAs were detected by indirect immunofluores-
cence (Inova Diagnostics, San Diego, CA) or antigen-
specific assay (enzyme-linked immunosorbent assay
or luminex-based assay) (2004–2013: FIDIS Multiplex,
Theradiag, Marne-la-Vallee, France; 2013–2018:
Immunocap250 CMIA, ThermoFisher Scientific, Wal-
tham, MA). Anti-GBM antibody testing was per-
formed by antigen-specific assay (2004–2013: FIDIS
Multiplex, Theradiag, Marne-la-Vallee, France; 2013–
2018: Immunocap250 CMIA, ThermoFisher Scientific,
Waltham, MA) and confirmed by immunoblot.
PLA2R was tested by immunofluorescence on
proteinase-digested paraffin embedded renal biopsies
using an anti-PLA2R1 primary antibody (Sigma-Aldrich,
St. Louis, MO) and an FITC conjugated IgG (Life Tech-
nologies, Carlsbad, CA) secondary. Biopsies were stained
for thrombospondin type 1 domain containing 7A
(THSD7A) by immunohistochemistry after standard heat
antigen retrieval method (pH 9; 95 C) with anti-
THSD7A antibody (Atlas, Bromma, Sweden), and stain-
ing was visualized using a DAKO EnVision kit (DAKO,
Glostrup, Denmark) as per manufacturer instructions.
Patients’ medical records were reviewed for de-
mographics, clinical findings of systemic vasculitis,
treatment, and clinical outcomes. Laboratory results
were reviewed for ANCAs, anti-GBM and anti-PLA2R
antibodies, and parameters of renal function.
Patients with a diagnosis of SLE based on clinical
features, serologic positivity for SLE such as positive
anti-nuclear antibody (ANA), double-stranded DNA (ds-
DNA), hypocomplementemia, and histopathologic find-
ings of lupus nephritis on kidney biopsy were excluded.1578Statistical analysis was performed using GraphPad
PRISM (SanDiego, CA). Continuous variables are reported
as median with range. Analysis was performed using
nonparametric tests including the Fisher exact test.RESULTS
Clinical and Laboratory Features
The cohort consisted of 15 patients—7 males and 8
females with a median age of 63 years (range: 18–79
years). Seven patients were white, 6 Asian, and 2 black
African. In 3 of 15 patients, biopsy-proven MGN was
diagnosed prior to the development of NCGN: case
number 1 had a diagnosis of MGN 8 months prior to
presenting with crescentic MGN and anti-GBM disease;
case number 13 had been diagnosed with anti-PLA2R-
positive MGN 9 years prior to presentation with NCGN
and had received treatment with tacrolimus; case
number 14 had a diagnosis of anti-PLA2R-positive
MGN in the context of hepatitis B (HBV) viremia 16
months prior to the development of NCGN. Despite
treatment of HBV, anti-PLA2R antibody titres remained
positive and the patient was started on treatment with
tacrolimus. Both these patients with anti-PLA2R-
positive NCGN were black African, and no ANCA or
anti-GBM antibody was detected in the serum at the
time of the development of NCGN.
In the remaining 12 patients, MGN and NCGN were
diagnosed at the time of the biopsy. One patient (case 7)
had a 2-year history of MPO–ANCA vasculitis; re-
biopsy during a relapse showed new spikes on the
GBM on silver staining and new subepithelial electron-
dense deposits consistent with a diagnosis of MGN.
ANCA testing was positive in 7 of 15 cases; specifically,
this was further identified asMPO-ANCA in 6 cases and as
PR3 –ANCA in one. Anti-GBM antibodies were detected
in 5 of 15 cases. One case was negative for anti-PLA2R
antibodies, ANCAs, and anti-GBM antibodies.
None of the patients had a history of SLE. ANA was
negative in all but one patient (case 6) who had a
positive ANA at a dilution of 1:160 and subsequently
had a negative ds-DNA. Rheumatoid factor was posi-
tive in one case (case 5) and negative in the remaining
14 patients. Complement C3 and C4 levels were normal
in all but one case. In this case (case 12), C4 was
transiently low at presentation at 0.07g/l, but this
normalized 6 days later; notably, the rheumatoid factor
and cryoglobulins were negative in this case. Anti-C1q
antibodies, cryoglobulins, and 24-hour urine collection
for proteinuria were not routinely tested in this cohort.
Hepatitis B and C andHIVwere negative in all but one
patient (case 14) who received treatment for HBV with
entecavir and at the time ofNCGNhad undetectable viral
load. This patient had normal complement level andKidney International Reports (2019) 4, 1577–1584
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available.
None of the patients had diabetes or diabetic ne-
phropathy, and none were taking thyrostatics or
levamisole-adulterated cocaine to our knowledge.
At presentation with NCGN, microscopic hematuria
was present in all but one patient who was anuric.
Proteinuria was present in 14 of 15 patients with a
median urinary protein-to-creatinine ratio of 819.5 mg/
mmol (range: 88–5600), and one was anuric at presen-
tation. A 24-hour proteinuria was recorded in 3 cases:
one with anti-GBM and MN (case 4: 11.2 g), and 2 with
MPO (case 7: 4.3 g; case 9: 2.1 g).
Median serum albumin was 24.5 g/l (range: 16–40).
Four patients required dialysis at presentation, and
only one recovered renal function after treatment but
was re-established on dialysis 2 years later; 3 of these
patients died during the follow-up period and the other
received a kidney transplant.
The clinical presentation, treatment, and outcomes
of patients with MGN and NCGN are summarized in
Table 1.
Pathologic Features
Light microscopy sampling showed a median of 18
glomeruli per biopsy (range: 9–45). A total of 25% of
all glomeruli were globally sclerosed, with median 7
(range: 1–12) per biopsy. All biopsies showed features
of MGN and NCGN (Table 2). Crescents were seen in all
biopsies (median 5 per biopsy; range: 1–22), and 30%
of the total glomeruli examined showed crescents that
were cellular, fibrous, or mixed fibrocellular. Silver
staining showed “spikes” and “holes” in 7 cases.
Interstitial fibrosis and tubular atrophy were noted in
all cases, with a median of 20% (range: 10%–75%).
Immunostaining (immunofluorescence or immuno-
peroxidase) revealed granular or linear, segmental to
global glomerular capillary wall IgG positivity in all
patients, with a circulating anti-GBM or anti-PLA2R
antibody, suggesting an immune complex–mediated
GN. Linear IgG positivity was observed in 3 of 5 pa-
tients with anti-GBM disease, and in the remaining 2 of
5, IgG staining was more granular. The ANCA-
associated rapidly progressive GN cases demonstrated
a pauci-immune picture with faint capillary wall IgG
positivity observed in 3 of 7 cases (Table 2). C3 was
positive in 13 cases with tissue available for staining.
Electron microscopy was performed in all patients, and
this showed features of MGN with subepithelial electron-
dense deposits. A total of 53% of cases showed stage II
MN, and 46% showed stage III alone or in combination
with stages I or IV. Few or rare mesangial deposits were
noticed in 3 caseswithANCA-associatedGN and in the one
case where no circulating antibody was detected (Table 2).Kidney International Reports (2019) 4, 1577–1584Immunofluorescence for PLA2R was performed in 12
cases with available tissue and was positive in 2 cases
with pre-existing anti-PLA2R–positive MGN that
demonstrated crescentic transformation. THSD7A
immunoperoxidase staining was negative in 11 cases
with available tissue that were also PLA2R negative.
The renal biopsy findings are detailed in Table 2, and a
selection of cases is illustrated in Figure 1.
Clinical Follow-up and Treatment
Follow-up data were available for all 15 patients for a
median of 72 months (range: 10–216 months; Table 1).
Patients were treated with steroids combined with
either cyclophosphamide and/or rituximab with or
without plasma exchange or mycophenolate mofetil. All
15 patients received prednisolone, 10 with cyclophos-
phamide and plasma exchange, and 6 in combination
with rituximab. Three patients were treated with
mycophenolate mofetil and steroids without cyclo-
phosphamide or rituximab, owing to frailty or patient
choice. Four patients required dialysis at presentation; 1
had a circulating MPO-ANCA and 3 had a detectable
anti-GBM antibody. One of the MGN and anti-GBM
patients (case 5) recovered renal function after the
initial episode and remained off dialysis for 2 years
before restarting dialysis. Two patients with anti-GBM
and MGN who required dialysis at presentation were
transplanted (cases 3 and 5) with good graft function at
3 and 17 years with no recurrence of MGN in the graft.
Anti-PLA2R antibodies were detected in 2 patients
with preexisting MGN prior to transformation to
NCGN; both were treated with rituximab and cyclo-
phosphamide with or without high-dose steroids, and
both had a significant improvement in renal function.
During the follow-up period, 4 patients died—3 with
MPO-ANCAs and 1 with anti-GBM disease.
DISCUSSION
Membranous glomerulonephritis with crescents is a
rare clinical entity that can be found in association with
circulating ANCAs, anti-GBM, or anti-PLA2R anti-
bodies. Historically, the first case of MGN with anti-
GBM disease was described by Klassen et al.11 in
1974, and since then, more than 40 cases have been
reported.8,12,13 Anti-GBM disease can develop on pre-
existing MGN, suggesting a transformation into cres-
centic glomerulonephritis. In our cohort, 5 cases were
associated with anti-GBM glomerulonephritis; only one
had confirmed MGN on biopsy 8 months prior to
presenting with anti-GBM GN and fulminant renal
failure. The cause of this transformation is not clear. A
number of factors such as solvent exposure and ciga-
rette smoking have been associated with the develop-
ment of anti-GBM disease,14 although this was not the1579
Table 1. Demographics, clinical and laboratory data at presentation, and follow-up
At presentation At follow-up
Case Age, yr Race Sex
Ab
(titer u/ml)
Prior
MGN Hematuria
Extrarenal
manifestations
Urine PCR
mg/mmol Alb, g/l
Creatinine,
mmol/l CRP, mg/l Treatment F/U, mo
eGFR,
ml/min per
1.73 m2
Creatinine,
mmol/l
UPCR,
mg/
mmol
1 79 Caucasian M GBM (64) Yes Yes Fatigue 5600 15 ESRD (1084) 321 Pred 93 ESRD—deceased ESRD ESRD
2 62 Caucasian F GBM (51) No Yes Fatigue,
breathlessness
2064 19 277 6.2 CYC, Pred 37 58 85 0
3 59 Asian F GBM (13) No Yes Malaise 2107 26 ESRD (810) 16 Pred 84 45 106 (tx) tx
4 18 Caucasian M GBM (61) No Yes Fatigue 260 40 102 2 CYC, Pred 134 >90 72 114
5 58 Caucasian F GBM (38) No Anuric Fatigue Anuric 23 ESRD (1125) 121 CYC, Pred, PEX 216 32 (tx) 139 (tx) tx
6 70 Asian M MPO (>134) No Yes Hemoptysis 379 16 ESRD (877) 200 CYC, Pred 10 ESRD—deceased ESRD ESRD
7 73 Caucasia M MPO (86) No Yes Malaise 4280 349 8 CYC, Pred, PEX 89 ESRD—deceased ESRD ESRD
8 66 Asian M MPO (>134) No Yes Fatigue, weight loss 88 31 560 61 RTX, CYC, Pred 39 24 224 10
9 34 Caucasian F MPO (19) No Yes Fatigue 2114 36 86 40 MMF, Pred 72 88 80 98
10 74 Asian F MPO (78) No Yes Fatigue, pulmonary
hypertension, protein
C deficiency
1053 22 217 38 RTX, CYC, Pred 10 51—deceased 94 101
11 73 Asian F MPO (74) No Yes Arthralgia 559 31 178 1.3 Pred, MMF 13 27 165 50
12 64 Caucasian M PR3 (544) No Yes Pulmonary
hemorrhage
113 35 263 411 CYC, Pred, RTX 81 80 83 62.5
13 63 Black F PLA2R (61) Yes Yes No 2086 20 483 2 RTX, CYC, Pred 10 44 108 40
14 44 Black F PLA2R (85) Yes No Fatigue 586 23 171 1.3 RTX, CYC 18 68 76 0
15 63 Asian M Neg No Yes Arthralgia 311 38 165 1.7 RTX, MMF, Pred 84 33 192 0
Ab, antibody; ANCA, anti-neutrophil cytoplasm antibodies; creat, creatinine; CRP, C-reactive protein; CyC, cyclophosphamide; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; F, female; F/U: follow-up; GBM, glomerular
basement membrane; M, male; MGN, membranous glomerulonephritis; MMF, mycophenolate mofetil; MPO, myeloperoxidase–ANCA; PCR, protein-creatinine ratio; PEX, plasma exhange; PLA2R, phospholipase A2 receptor; PR3, anti-proteinase 3
ANCA; pred, prednisolone; RTX, rituximab; tx, transplant; UPCR, urine protein-to-creatinine ratio.
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Table 2. Biopsy findings
Case
no.
Antibody
(serum)
Total
no glomeruli
Globally
sclerotic/
obsolete Crescents Light microscopy Silver stain IFTA IF/IP
Mesangial
IC
EDD
stage
PLA2R
staining
1 GBM 12 0 12 MGN, crescents Spikes None Granular capillary wall IgG, C1q,
C3, C4
Linear capillary wall IgA and IgM
Not seen III-IV No tissue
2 GBM 22 3 7 MGN, focal segmental
necrotizing GN with crescents
NA 10% Granular capillary wall IgG
IF no glomeruli
Not seen II-III Neg
3 GBM 15 9 3 Membranoproliferative GN,
MGN
NA 30% Granular capillary wall IgM, C3,
C1q, linear capillary wall IgG,
scanty granular mesangial IgM, C3
Not seen I-II Neg
4 GBM 30 3 11 Focal segmental proliferative
GN, MGN
NA 15% Linear capillary wall IgG, IgA, C3 Not seen II Neg
5 GBM 22 0 22 Crescentic GN, arteritis, MGN Spikes Granular capillary wall C3, linear
capillary wall IgG, IgA, IgM, C1q,
C4,
Not seen II No tissue
6 MPO 12 8 3 MGN, focal necrotizing GN
with crescents
NA 50% No glomeruli Few peripheral III-IV Neg
7 MPO 45 9 3 MGN, focal segmental GN with
crescents
Spikes 50% Capillary wall granular IgG, IgM,
C3
Segmental scars IgM, C1q, C3
Few II-III No tissue
8 MPO 18 7 5 Focal segmental necrotizing
GN, MGN
NA 75% Granular capillary wall C3
Mesangial IgM
k, l positive
Not seen I-II Neg
9 MPO 12 4 1 Focal segmental
glomerulosclerosis, MGN
NA 20% Capillary wall segmental IgM, C3
Segmental mesangial IgG, IgM, C3
Not seen I-II Neg
10 MPO 21 8 6 MGN, focal segmental
proliferative and necrotizing
GN
Holes 20% Faint granular capillary wall IgG,
IgM, C3
Not seen III Neg
11 MPO 18 8 1 MGN, atrophy, small
fibrocellular crescent
Segmental
irregularities
50% Granular capillary wall IgGþ, C3þ,
k, l positive
Rare II-III Neg
12 PR3 9 1 3 Focal necrotizing GN with
cellular crescents, MGN
Holes 10% IF no glomeruli
Mesangial, C3, C1q
k, l positive
Not seen II Neg
13 PLA2R 11 1 7 MGN, crescentic GN, fibrous
and cellular crescents
Spikes 15% Granular capillary wall IgG, C3
k, l positive
Not seen II-III Pos
14 PLA2R 27 3 6 MGN, thickened capillary
walls, cellular crescents
Spikes 20% Granular capillary wall IgGþ, IgM,
k, l positive
C3 negative
Not seen I-IV Pos
15 Neg 25 12 2 MGN with mesangial IgA and
crescents
Spikes, holes 25% Granular capillary wall IgG,
mesangial IgA and IgM,
k, l positive
Present I-IV Neg
EDD, electron dense deposits; GBM, glomerular basement membrane; GN, glomerulonephritis; IC, immune complexes; IF, immunofluorescence; IFTA, interstitial fibrosis tubular atrophy;
IP, immunoperoxidase; MGN, membranous glomerulonephritis; NA, not available; neg, negative; pos, positive; PLA2R, phospholipase A2 receptor.
A Nikolopoulou et al.: Membranous Glomerulonephritis With Crescents CLINICAL RESEARCHcase in our patients. Approximately half of concomitant
MGN and anti-GBM glomerulonephritis are diagnosed
together at presentation,12,15 making it difficult to
determine whether MGN pre-dated the development of
anti-GBM GN. It is known that the presence of HLA
DRB1 and HLA DQ1 are strongly associated with sus-
ceptibility to anti-GBM disease,16,17 and MGN,18
respectively, and it is possible that the coexistence of
these alleles leads to an increased risk for developing
dual glomerulopathy.
In our series of MGN and anti-GBM glomerulone-
phritis, one patient was anuric at presentation, and the
rest had microscopic hematuria and significant protein-
uria as evidenced by a median urinary protein-to-
creatinine ratio of 2085 mg/mmol (range: 260–5600).
Three of these patients required dialysis at presentation,
and one recovered renal function following treatmentKidney International Reports (2019) 4, 1577–1584with plasmapheresis, cyclophosphamide, and steroids.
Treatment of MGN with anti-GBM glomerulonephritis
should probably be focused on the anti-GBM element of
the condition. Rituximab is a successful treatment for
MGN19–22 and has been suggested as an alternative
treatment for refractory MGN and anti-GBM disease.23
Interestingly, none of the patients with combined
MGN and anti-GBM disease had alveolar hemorrhage,
suggesting a renal limited variant of the disease. Primary
MGN is associated with endogenous podocyte antigens
such as the PLA2 receptor,24 or less commonly with the
THSD7A antigen.25 In anti-GBM disease, the antibodies
are primarily targeting the noncollagenous domain 1 of
the a3 chain of type IV collagen. Jia et al.4 showed that in
cases of combined MGN and anti-GBM disease, these
antibodies do not react with all 5 of the a chains of type
IV collagen, and that serum from patients with MGN has1581
CLINICAL RESEARCH A Nikolopoulou et al.: Membranous Glomerulonephritis With Crescentsno reactivity against any of the 5 a chains, suggesting a
different pattern of disease. The renal biopsies in our
anti-GBM and anti-PLA2R antibody positive cases
demonstrated a combination of linear and granular IgG
staining, suggesting an immune complex–mediated pa-
thology. However, capillary wall IgG positivity was
either faint or absent in the ANCA cases, pointing to a
pauci-immune process. C3 was positive in 4 cases in both
granular and linear deposition, suggesting subepithelial
deposits as well as continuous immunoglobulin and C3
deposition along the capillary walls.
One of the first cases of a crescentic MGN associated
with ANCAs was described in 1993 by Gaber et al.9
This was a C-ANCA positive case with multiple
extrarenal manifestations (pulmonary capillaritis, otitis,
and recurrent sinusitis) treated with prednisolone and
cyclophosphamide.9 In our series, 7 patients had a
detectable circulating ANCAs that was further identi-
fied as MPO-ANCA in all but one case that had a
circulating PR3-ANCA. PLA2R antibodies were not
found in this subgroup, and this coexistence appears
to be extremely rare, with just 3 cases described so
far.10,26 The presence of ANCAs was associated with
significant renal disease, with 2 patients requiringFigure 1. Microscopy findings of cases. Case 2: Glomerular tuft with a
thickened capillary wall with spikes (b). Electron microscopy shows s
effacement (c). Case 14: IgG staining revealed granular staining along the
strong granular staining along the capillary walls (e). Fibrocellular cresce
1582dialysis at presentation. The patient with PR3-ANCA
had significant systemic disease and presented with
alveolar haemorrhage. Nephrotic range proteinuria
(>300 mg/mmol) was present in 5 of 7 of these patients,
and all had microscopic hematuria. All these patients
with crescentic MGN with ANCAs received induction
therapy with prednisolone; 5 also received cyclophos-
phamide, in 3 cases in combination with rituximab.
Plasmapheresis combined with prednisolone and
cyclophosphamide was performed on one patient, and
one received prednisolone with mycophenolate mofetil.
Three of the patients in this subgroup died during the
follow-up period, but the remaining 4 had a glomerular
filtration rate of >24 ml/min per 1.73 m2 at follow-up.
In one case, the crescentic GN pre-dated the develop-
ment of MGN; however, the dual glomerulopathy was
diagnosed simultaneously on biopsy in all other cases
at the time of presentation. In our series, all patients
with MGN and ANCA-associated crescentic GN had
extra renal manifestations, ranging from fatigue and
malaise to arthralgia and hemoptysis, but none had
ENT symptoms.
Two patients were PLA2R positive only and had a
diagnosis of MGN 1 and 8 years prior to the crescenticcellular crescent filling Bowman’s space (a); glomerulus showing
ubepithelial electron dense deposits and extensive foot process
capillary walls (d). Immunofluorescence for PLA2R staining revealed
nt engulfing the glomerulus is shown (f).
Kidney International Reports (2019) 4, 1577–1584
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treatment for MGN with tacrolimus and underwent a
repeat biopsy to investigate rising serum creatinine.
Rodriguez et al.3 describe a series of 19 cases with
crescentic MGN without ANCAs or anti-GBM anti-
bodies, 6 of which were PLA2R positive on biopsy; all
had hematuria and proteinuria at presentation. Four-
teen of these patients were treated with immuno-
suppressive therapy, and 4 progressed to end-stage
renal disease. In our series, both patients with
PLA2R-positive MGN and NCGN were treated with
rituximab and cyclophosphamide, with a significant
improvement in renal function and resolution of
proteinuria. One of these patients had significantly
less proteinuria at the time of the crescentic trans-
formation and was also on treatment for hepatitis B
with entecavir. The viral load at the time of crescentic
GN was undetectable; however, it is possible that the
previous immunologic response to the hepatitis B
virus triggered the exposure and possibly the
conformational change of podocyte antigens leading
to antibody production and the development of
PLA2R-positive MGN. PLA2R-positive MGN in
hepatitis B–infected patients has been described and
appears to affect approximately two thirds of patients
with hepatitis B virus and MGN.27 The one case in
our series with MGN and NCGN on biopsy, with no
detectable circulating antibody, presented with acute
kidney injury, proteinuria, and arthralgia. Treatment
with steroids, rituximab, and mycophenolate mofetil
resulted in stabilization of renal function and reso-
lution of proteinuria.
In summary, the cases in our series represent the
distinct and rare entity of MGN with NCGN. The
renal function at presentation in association with the
presence of antibodies seems to be influencing the
clinical outcome. MGN associated with anti-GBM
and ANCA NCGN should be treated initially as for
anti-GBM disease and ANCA-associated vasculitis,
respectively. A repeat renal biopsy should be
considered in patients with MGN and an acute dete-
rioration in renal function, as this could suggest a
superimposed crescentic pathology. Crescentic trans-
formation in MGN in the presence of anti-PLA2R
antibodies should also be treated as a rapidly pro-
gressive GN. In the patients that received a renal
allograft, there was no recurrence of MGN or NCGN.
Further studies of this rare glomerulopathy are
needed to understand the mechanisms underlying the
development of crescentic lesions in MGN.DISCLOSURE
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